Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Quantitative Assessment of the Association between ABC Polymorphisms and Osteosarcoma Response: a Meta-analysis

  • Chen, Xu (Department of Clinical Laboratory, First Affiliated Hospital of Soochow University) ;
  • Jiang, Min (Department of Clinical Laboratory, First Affiliated Hospital of Soochow University) ;
  • Zhao, Rui-Ke (Department of Clinical Laboratory, First Affiliated Hospital of Soochow University) ;
  • Gu, Guo-Hao (Department of Clinical Laboratory, First Affiliated Hospital of Soochow University)
  • Published : 2015.06.26
Download PDF
⟨ Previous Next ⟩

Abstract

Background: ABC proteins are one key type of transport superfamilies which undertake majority of drug transport, which affect the osteosarcoma response to chemotherapeutics. Previous studies have suggested the association between ABC polymorphisms and osteosarcoma response. However, the results of previous studies remain controversial. Therefore, we perform a meta-analysis to get a more precise estimation of this association. The association between ABC polymorphisms and osteosarcoma response was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs). Three polymorphisms of ABC including ABCB1 rs1128503, ABCC3 rs4148416 and ABCC2 rs717620 polymorphism were investigated. Overall, significant association was observed between ABCC3 rs4148416 polymorphism and osteosarcoma response under allele contrast (T vs. C: OR=1.73, 95%CI=1.09-2.74, P=0.019), homozygote comparison (TT vs. CC: OR=2.00, 95%CI=1.25-3.23, P=0.004), recessive genetic model (TT vs. TC/CC: OR=1.80, 95%CI=1.14-2.84, P=0.011) and dominant genetic model (TT/TC vs. CC: OR=1.70, 95%CI=1.20-2.42, P=0.003). Moreover, significant association was also observed in Caucasian population rather than Asian population for ABCB1 rs1128503 polymorphism. We conclude that ABCC3 rs4148416 polymorphism was significantly associated with poor osteosarcoma response and ABCB1 rs1128503 polymorphism was significantly associated with good osteosarcoma response in Caucasian population rather than Asian population.

Keywords

References

  1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  2. Bielack SS, Kempf-Bielack B, Delling G, et al (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 20, 776-90. https://doi.org/10.1200/JCO.20.3.776
  3. Caronia D, Patino-Garcia A, Perez-Martinez A, et al (2011). Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One, 6, 26091. https://doi.org/10.1371/journal.pone.0026091
  4. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  5. Hayes JD, Pulford DJ (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30, 445-600. https://doi.org/10.3109/10409239509083491
  6. He JP, Hao Y, Wang XL, et al (2014). Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev, 15, 5967-76. https://doi.org/10.7314/APJCP.2014.15.15.5967
  7. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  8. Li JZ, Tian ZQ, Jiang SN, Feng T (2014). Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy. Genet Mol Res, 13, 3186-92. https://doi.org/10.4238/2014.April.25.3
  9. Li M, Zhu Y, Zhang H, et al (2014). Delivery of inhibitor of growth 4 (ING4) gene significantly inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells. Sci Rep, 4, 7380. https://doi.org/10.1038/srep07380
  10. Liu S, Yi Z, Ling M, et al (2014). Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy. Tumour Biol, 35, 9897-904. https://doi.org/10.1007/s13277-014-1917-x
  11. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  12. Ottaviani G, Jaffe N (2009). The epidemiology of osteosarcoma. Cancer Treat Res, 152, 3-13. https://doi.org/10.1007/978-1-4419-0284-9_1
  13. Redlich G, Zanger UM, Riedmaier S, et al (2008). Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry. J Proteome Res, 7, 4678-88. https://doi.org/10.1021/pr800231w
  14. Wei L, Song XR, Wang XW, Li M, WS Zu (2006). [Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance]. Zhonghua Zhong Liu Za Zhi, 28, 445-8.
  15. Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS (2012). Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer, 118, 1856-67. https://doi.org/10.1002/cncr.26472
  16. Xiaohui S, Aiguo L, Xiaolin G, et al (2014). Effect of ABCB1 polymorphism on the clinical outcome of osteosarcoma patients after receiving chemotherapy. Pak J Med Sci, 30, 886-90.
  17. Yang J, Wang ZG, Cai HQ, Li YC, Xu YL (2013). Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy. Asian Pac J Cancer Prev, 14, 4595-8. https://doi.org/10.7314/APJCP.2013.14.8.4595
  18. Zhou SF, Di YM, Chan E, et al (2008). Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab, 9, 738-84. https://doi.org/10.2174/138920008786049302

Cited by

  1. Association between ABCB1 polymorphisms and haplotypes and Alzheimer’s disease: a meta-analysis vol.6, pp.1, 2016, https://doi.org/10.1038/srep32708
  2. Advances and challenges in hereditary cancer pharmacogenetics vol.13, pp.1, 2017, https://doi.org/10.1080/17425255.2017.1233965